NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.

@article{Farah2019NOTCHSI,
  title={NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.},
  author={Elia Farah and Chaohao Li and Lijun Cheng and Yifan Kong and Nadia A Lanman and Pete E. Pascuzzi and Gabrielle Renee Lorenz and Yanquan Zhang and Nihal Ahmad and Lang Li and Tim Ratliff and X. Shawn Liu},
  journal={The Journal of biological chemistry},
  year={2019},
  volume={294 21},
  pages={
          8543-8554
        }
}
Prostate cancer is the second leading cause of cancer death among men in the United States. The androgen receptor (AR) antagonist enzalutamide is a Food and Drug Administration-approved drug for treatment of patients with late-stage prostate cancer and is currently under clinical study for early-stage prostate cancer treatment. After a short positive response period, tumors will develop drug resistance. In this study using RNA-Seq and bioinformatics analyses, we observed that NOTCH signaling is… CONTINUE READING
1
Twitter Mention